There is no cure for bladder cancer? This ADC delivers a 44% mitigation rate

Urinary skin cancer is a common type of bladder cancer, which has been approved for treatment of immunotherapyBut ASCO said in an official press release that patients will be left in a "no-drug" situation once advanced in the treatment of platinum-based chemotherapy and immunocheckpoint inhibitors, which are only effective for about 20 percent of patientsand enfortumab vedotin offers patients a new hopeThis antibody-linked drug can target the highly expressed Nectin-4 protein in urinary skin cancer, and deliver the microtubule interference drug MMAE to cancer cells, playing a lethal roleBased on the results of a Phase 1 clinical trial, the FDA has awarded it breakthrough therapy to determine that the disease is still advanced after immunocheckpoint inhibitor treatment, or advanced or metastatic urinary skin cancerenfortumab vedotin (Photo: Seattle Genetics)the therapeutic potential of this antibody-linked drug has once again been tested in a Phase 2 clinical trialIn 125 patients, the objective remission rate was 44%, of which the total remission rate was 12%For patients with various difficult treatments, the treatment is also full of potential: 41 percent of patients who have previously received at least three treatments, 41 percent in patients with PD-1 and PD-L1 treatments, and 38 percent in patients with liver metastasesthese results are a great boost to the researchersMany experts noted in a press release that there are very limited treatment options available to patients with both chemotherapy and immunotherapyAnd the results of this study, let us see the treatment of these difficult patients a new hope!currently, the therapy is in Phase 3 clinical trialsThe researchers also look forward to large-scale studies to confirm their efficacyMeanwhile, based on the results of the Phase 2 trial, Seattle Genetics and Astellas plan to submit their listing applications to the FDA this yearReferences:Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent In Patients MostCommon Type of Advanced Urothelial (Bladder) Origind June 3, 2019, from https://seattlegenetics.gcs-web.com/news-releases/news-release-details/seattle-genetics-and-astellas-announce-antibody-drug-conjugate 2) Novel Targeted-Antibody Treatment Produceed Responses in Nearly Half of Patients With Advanced UrotheliCancer, Retrieved June 3, 2019 https:// Original title: ASCO With no cure for bladder cancer, this ADC delivers a 44% relief rate!